GLUCOSYLMORANOLINE DERIVATIVES

Abstract: Glucosylmoranoline derivatives useful as remedy for diabetes are represented by the following general formula (I) wherein B,A and R have the following meanings : B: Substituted or unsubstituted;cyclic or chain; and saturated or unsaturated hydrocarbon; A: O,S,NH,NR,C=O or a combination of two or more of them or a direct combination of B with R; and R: A group selected from a group of the following (1) to (3) : (1) Substituted or unsubstituted; cyclic or chain; and saturated or unsaturated hydrocarbon, (2) substituted or unsubstituted aromatic hydrocarbon; and (3) substituted or unsubstituted heterocyclic compound; except the case where B-A-R is any of the following (1) to (3) : (1) hydrogen; (2) lower alkyl; and (3) chain or cyclic hydrocarbon having one or more hydroxyl groups. These derivatives exhibit less toxicity and higher inhibitory action against blood sugar level increase than moranoline and glucosylmoranoline derivatives having a formula similar to formula (1) wherein B-A-R is a hydrocarbon having hydroxyl group(s).

Description: The present invention relates to a compound having the following general formula (I) and exhibiting inhibitory action against blood sugar increase. wherein B, A and R have the following meanings : B : Chain or cyclic C₁₋₁₅ alkylene, C₂₋₁₅ alkenylene or C₂₋₁₅ alkynylene, unsubstituted or substituted with at least one substituent selected from halogen, hydroxyl, mercapto, amino, aromatic hydrocarbon residue or heterocyclic residue; A : O, S, NH, NR, C=O or a combination of two or more of them or a direct combination of B with R; and R : A group selected from the following (1) to (3) : (1) Chain or cyclic alkyl, alkenyl or alkynyl, unsubstituted or substituted with at least one substituent selected from halogen, hydroxyl, mercapto, amino, aromatic hydrocarbon residue or heterocyclic residue; (2) phenyl or naphthyl unsubstituted or substituted with at least one substituent selected from chain or cyclic alkyl, alkenyl or alkynyl, halogen, hydroxyl, mercapto, amino, carboxyl, alkoxycarbonyl, aromatic hydrocarbon residue or heterocyclic residue; (3) heterocyclic radical selected from pyridinyl, morpholinyl, piperidinyl and benzimidazolyl, unsubstituted or substituted with at least one substitutent selected from chain or cyclic alkyl, alkenyl or alkynyl, halogen, hydroxyl, mercapto, amino, carboxyl, alkoxycarbonyl, aromatic hydrocarbon residue or heterocyclic residue, except the case where B-A-R is any of the following (1) to (3) : (1) hydrogen; (2) C₁-C₃ alkyl; and (3) chain or cyclic hydrocarbon having one or more hydroxyl groups. (Prior Art) Moranoline has the following chemical structure and is very useful as a pharmaceutical exhibiting therapeutic effect on diabetes mellitus. Moranoline was first isolated from mulberry bark which is a kind of Chinese drug (cf. Yagi, et al: Nippon Nôgei Kagaku Kaishi, vol. 50, page 571, 1976; Japanese Laid Open Publication 52/83951). Later, this compound was able to be manufactured by a fermentation method using a microorganism belonging to Streptomyces genus. (cf. Japanese Laid Open 54/84094). The present inventors have conducted studies in order to find more excellent agents for diabetes and synthesized various derivatives of this compound. During the stage of the studies, they manufactured the compounds wherein B-A-R in the general formula (1) is hydrogen or lower alkyl and filed the patent application for them (cf. Japanese Examined Publication 24798/85 and others). The present inventors have continued the study, synthesized the compounds wherein B-A-R is a hydrocarbon having hydroxyl group(s), confirmed that they are novel substances exhibiting useful pharmacological action, and filed the patent application for them (cf. Japanese Patent Application 227601/86). (Problems to be solved by the Invention) An object of the present invention is to manufacture compounds exhibiting less toxicity and higher inhibitory action against blood sugar level increase as a result of the studies on the usefulness of the above moranoline derivatives as remedy for diabetes. (Means to solve the Problems) The present inventors have conducted extensive studies to meet with the above object, found that the compounds of the above-given formula (I) are suitable for such an object, and achieved the present invention. Compounds of the present invention are novel and have not been disclosed in the prior art literatures. The present invention compounds have N-substituted glucosyl-moranoline as fundamental skeleton. During the course of the studies for the above-mentioned patent applications having glucosylmoranoline skeleton and a substituent at N, the present inventors have found that various compounds of the present invention exhibit the same pharmacological action as the above-mentioned ones do and are useful as pharmaceuticals and achieved the present invention. The characteristic feature of the present invention compounds in terms of chemical structure is that they have N-substituted glucosylmoranoline as fundamental skeleton and a substituent of a formula B-A-R at the position of nitrogen. The present invention will be further illustrated as follows: The compounds of the present invention are basic and, accordingly, they may form various salts with acids. When such salts are pharmacologically acceptable, they are, of course, included in the present invention. The compounds of the present invention can be manufactured by subjecting 4-O-alpha-D-glucopyranosylmoranoline to a conventional method which is known in organic chemistry. Manufacture of the present invention compounds is clearly supported by the examples which will be given later. The inhibitory action of the present invention compounds against blood sugar level increase can be confirmed as follows: Measurement of alpha-Glucosidase Inhibiting Action in vitro. Inhibitory activity measurement against sucrase and maltase in vitro of the test compounds using roughly purified enzyme preparation (purified in accordance with a method of Takesue, 1969) obtained from rabbit small intestine mucosa is carried out as follows. The enzymatic reaction is conducted in such a manner that, to 40 µl of enzyme solution diluted with 0.4M phosphate buffer (pH 7.0) are added 20 µl of a solution of a test compound in the same buffer and 140 µl of a solution of a substrate (50mM sucrose or 50mM maltose) in the same buffer and the mixture is subjected to a reaction at 37°C for 30 minutes. The reaction is then stopped by adding 400 µl of 3N barium hydroxide and 400 µl of 5% zinc sulfate solution. The reacted amount of the enzyme is determined as a glucose amount contained in 200 µl of the supernatant liquid of the reaction by adding 3 ml of glucoseoxidase reagent (Boehringer-Mannheim) followed by reacting at ambient temperature for 30 minutes and measuring the absorbance at 420 nm. The 50% inhibition concentration (IC₅₀) of the compound to sucrase and maltase is calculated by expressing the values (as measured by the above method with five different concentrations) as an inhibitory rate (%) to the control. The result is given in Table 1. Example No. (1) Sucrase (2) Maltase 1 15.5 23.5 3 17.2 248.9 4 10.0 34.2 6 30.8 192.5 8 24.8 173.0 9 6.4 223.6 12 21.9 2.0 13 22.9 262.1 14 6.8 168.6 17 5.2 77.9 18 19.8 44.6 20 9.7 284.9 22 16.1 40.9 25 14.0 69.2 Unit: µg/ml. It is apparent that the present invention compounds exhibit excellent glucosidase activity inhibiting action. Inhibitory Action against Increase in Blood Sugar Level in Rats: SD-Strain rats (5 weeks age ; male; each group comprising 4 to 5 rats) were fasted overnight and 1 ml/100 g body weight of aqueous solution of sucrose (2 g/10 ml) containing 30 mg test compound was given per os through a stomach tube. Blood was taken from tail vein immediately before the administration and at 30, 60, 90, 120 and 180 minutes thereafter and blood sugar levels were measured by a glucose oxidase method (using the assay kit prepared by Boehringer Mannheim). Based on the values obtained above, a graph was drawn using the abscissa for time and ordinate for blood sugar level and the area (▵ AUC) under the time-blood sugar increase curve was determined. A group administered only with water and another group administered only with sucrose were named a basal group (group B) and a control group (group C), respectively. Then the inhibitory rate for an increase in ▵ AUC 180 minutes after administration of the test compounds (group T) was calculated from the following expression. The result is given in Table 2. Example No. 1 3 5 6 8 9 12 13 14 17 18 19 20 22 25 Inhibitory Rate(%) 68.6 73.2 94.8 69.9 54.8 64.5 46.6 77.1 86.9 80.2 47.9 54.0 76.8 48.4 84.4 It is apparent that the present invention compounds surely exhibit inhibitory action against blood sugar level increase in rats. In the meanwhile, a compound (Example 1) of the present invention was given orally to mice (5 g/kg) and its toxicity was tested but there was no case of death. When the present invention compound was administered as pharmaceuticals, it is given as it is or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (preferably 0.5 to 90%) of the compound in a pharmaceutically-acceptable, nontoxic and inert carrier to animals including human being. Carriers applicable are solid, semisolid or liquid diluents, fillers and other auxiliary agents for pharmaceutical preparations. It is desired that such pharmaceutical preparations are given in a unit dose form. The present invention pharmaceutical preparations may be given via mouth, into tissue, to local place (e.g. via skin), or via rectum. Needless to say, administration is conducted by a form suitable for such a route of administration. For example, oral administration is most preferred. It is desired that the dose as a remedy for diabetes is adjusted after considering the the state of the patient (e.g. age, body weight, etc.), administration route, and type and degree of the diseases and, usually, the range of 10 to 2000 mg per day (more preferably 100 to 600 mg per day) as an effective ingredient amount of the present invention is desired. In some cases, less dose may be sufficient while in other case, more doses may be necessary. It is desired that the dose may be given dividedly several times in a day. (Working Examples) The present invention will be further illustrated by way of the examples for the manufacture of the present invention compounds though it is to be understood that the present invention is no t limited thereto. Example 1. 4-O-alpha-D-Glucopyranosyl-N-(p-methylbenzyl)-moranoline. 4-O-alpha-D-Glucopyranosylmoranoline (5 g) was dissolved in 50 ml of dimethylformamide. Anhydrous potassium carbonate (6.4 g) was added thereto. Then, with stirring, 7.1 g of alpha-bromo-p-xylene was added. The mixture was made to react at 100°C for 5 hours and filtered. After evaporating the solvent, the residue was dissolved in water and partitioned with chloroform. Aqueous layer was treated with a column of 50 ml of strongly acidic ion exchange resin (Dowex 50W × 2 (H⁺)), the column was well washed with water, eluted with 1N ammonia water, solvent was evaporated from the eluate in vacuo, the resulting powder (5.8 g) was dissolved in methanol, and 3.9 g of p-toluenesulfonic acid monohydrate was added. The solution was concentrated in vacuo and, when crystals were separated out, the concentrating operation was stopped and ethanol was added so that crystals were fully separated out. The mixture was filtered and 7.2 g of crystals were obtained. They were dissolved in water, the solution was applied to a column of 30 ml of Diaion SA-11A and the column was well washed with water. The solution which passed through and the washing were combined and the solvent was evaporated therefrom followed by drying to give 4.5 g of crystalline powder. M.p. 116-119°C. [α] 24 / D = +50.5° (c = 0.94%, water). Elem Anal for C₂₀H₃₁NO₉ ·½H₂O Calculated (%) C : 54.79 H : 7.36 N : 3.19 Found (%) C : 54.92 H : 7.53 N : 3.31 Example 2. 4-O-alpha-D-Glucopyranosyl-N-(4-methylcarbamoylbutyl)moranoline p-toluenesulfonate. The same operation as in Example 1 was conducted using N-methylcarbamoylbutyl bromide to give 5.0 g of the desired product, m.p. 125-127°C. [α] 24 / D = +47.7° (c = 1.0%, water) Elem Anal for C₂₅H₄₂N₂O₁₃S Calculated (%) C : 49.17 H : 6.93 N : 4.59 Found (%) C : 48.73 H : 7.08 N : 4.66 Example 3. 4-O-alpha-D-Glucopyranosyl-N-(3-methylcrotyl)moranoline p-toluenesulfonate. 4-O-alpha-D-Glucopyranosylmoranoline (1.00 g), 1.60 g of anhydrous potassium carbonate and 3.00 g of 1-bromo-3-methyl-2-butene were mixed with 15 ml of dimethyl sulfoxide, the mixture was stirred for 1 hour at ambient temperature, and heated with stirring at 100-110°C for 3 hours. After cooled, the mixture was filtered. The insoluble matter was washed with 10 ml of dimethyl sulfoxide and the washing was combined with the filtrate. To this was added 30 ml of water, the mixture was transferred to a separating funnel and washed 2 times with each 20 ml chloroform. The aqueous layer was passed through a column of 30 ml of strongly acidic ion exchanger (Dowex 50W × 2 (H⁺)), the column was washed with water until the washing became neutral, and eluted with 200 ml of 1.4% ammonia water. To the eluate was added small amount of antifoaming agent, the mixture was concentrated to dryness in vacuo, and 0.67 g of crude product was obtained. This was dissolved in 5 ml of ethanol, 0.70 g of p-toluene-sulfonic acid was dissolved therein, ethanol was evaporated in vacuo from the mixture, and the residue was dried and recrystallized from ethanol to give 0.23 g of colorless powder. M.p. 194-196°C. [α] 24 / D = +48.6° (c = 1.144, water). Elem Anal for C₁₇ H₃₁NO₉·C₇H₈O₃S Calculated (%) C : 50.69 H : 6.95 N : 2.48 Found (%) C : 50.26 H : 7.22 N : 2.48 Example 4. 4-O-alpha-D-Glucopyranosyl-N-(p-bromobenzyl)moranoline. 4-O-alpha-D-Glucopyranosylmoranoline (5 g) and 6.4 g of anhydrous potassium carbonate were added to 50 ml of dimethylformamide, then 9.6 g of 4-bromobenzyl bromide was added, and the mixture was made to react at ambient temperature for 4 hours. The precipitate was removed by filtration, the solvent was evaporated in vacuo, chloroform was added to the residue, the precipitate formed was collected by filtration, dissolved in water, and partitioned with ethyl acetate. Aqueous layer was treated with a column of 50 ml of strongly acidic ion exchange resin (Dowex 50W × 2 (H⁺)), the column was well washed with water, eluted with 1N ammonia water, the eluate was concentrated in vacuo, and the concentrate was treated with activated charcoal followed by evaporating to dryness. Recrystallization from methanol gave 4.7 g of crystals, m.p. 210-212°C. [α] 24 / D = +55.5° (c = 1.0%, water). Elem Anal for C₁₉H₂₈NO₉Br Calculated (%) C : 46.16 H : 5.71 N : 2.83 Found (%) C : 46.03 H : 5.87 N : 2.88 Example 5. 4-O-alpha-D-Glucopyranosyl-N-hexylmoranoline p-toluenesulfonate. A mixture of 1.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 1.60 g of anhydrous potassium carbonate, 2.00 g of 1-bromohexane and 15 ml of dimethyl sulfoxide was stirred at ambient temperature for 1 hour, heated at 100-110°C with stirring for 3 hours, allowed to cooled, filtered, and the insoluble matter was washed with 5 ml of dimethyl sulfoxide. The filtrate was combined with the washing, 20 ml of water was added to the combined liquid, the mixture was transferred to a separating funnel, and washed twice with chloroform (20 ml each). The aqueous layer was applied to a column of 30 ml of strongly acidic ion exchange resin (Dowex 50W × 2 (H⁺)), the column was washed with water, eluted with 200 ml of 1.5% ammonia water, small amount of antifoaming agent was added to the eluate, and the mixture was concentrated in vacuo to dryness to give 0.42 g of pale brown substance. This was dissolved in 5 ml of ethanol, 0.42 g of p-toluene-sulfonic acid was added, and ethanol was evaporated from the mixture in vacuo. The residue was dissolved in 5 ml of ethanol, the solution was allowed to stand after addition of 3 ml of acetone, and the resulting precipitate was filtered to give 0.32 g of colorless powder. M.p. 194-195°C. [α] 24 / D = +55.6° (c = 1.151, water). Elem Anal for C₁₈H₃₅NO₉ · C₇H₈O₃S Calculated (%) C : 51.62 H : 7.45 N : 2.41 Found (%) C : 51.91 H : 7.40 N : 2.39 Example 6. 4-O-alpha-D-Glucopyranosol-N-(beta-phenylethyl)moranoline To 50 ml of dimethylformamide were added 5 g of 4-O-alpha-D-glucopyranosylmoranoline and 6.4 g of anhydrous potassium carbonate. To this was added 7.1 g of beta-phenylethyl bromide with stirring and the mixture was made to react at 100°C for 5 hours. The reaction solution was filtered to remove the precipitate, the filtrate was concentrated in vacuo, then chloroform was added thereto, the precipitate obtained was collected by filtration, dissolved in water, and the solution was treated with a column of 60 ml of strongly acidic ion exchanger (Dowex 50W × 2 (H⁺)). The column was well washed with water followed by eluting with 1N ammonia water. The solvent was removed in vacuo from the eluate and the residue was treated with a column of 40 g of silica gel. The column was developed with an eluting solution of chloroform-methanol (1:1) to collect a fraction containing the desired product which was evaporated to dryness in vacuo to give 3.7 g of powder. No clear melting point but it started to melt at 87-89°C and finished the melting at 103-106°C. [α] 24 / D = +71.2° (c = 0.98, water). Elem Anal for C₂₀H₃₁NO₉ Calculated (%) C : 55.94 H : 7.28 N : 3.26 Found (%) C : 55.64 H : 7.25 N : 3.55 Example 7. 4-O-alpha-D-Glucopyranosyl-N-(beta-cyclohexylethyl)-moranoline. The same operation as in Example 6 was conducted with an exception of the use of beta-cyclohexylethyl bromide to give 4.0 g of the product. M.p. 88-90°C [α] 24 / D = +65.3° (c = 1.00, water). Elem Anal for C₂₀H₃₇NO₉ Calculated (%) C : 55.16 H : 8.56 N : 3.22 Found (%) C : 54.83 H : 8.78 N : 3.30 Example 8. 4-O-alpha-D-Glucopyranosyl-N-(p-methoxybenzyl)moranoline. A mixture of 2.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 4.24 g of anhydrous potassium carbonate, 5.50 g of p-methoxybenzyl chloride and 20 ml of dimethylformamide was stirred at 60°C for 1 hour and heated with stirring at 100-105°C for 6 hours. The reaction solution was filtered when it is still hot and the insoluble matter was washed with small amount of dimethylformamide. The filtrate was combined with the washing and dimethylformamide was removed in vacuo therefrom. The residue was washed twice with each 20 ml ether. The ether-insoluble matter was dissolved in water, treated with a column of 50 ml of strongly acidic ion exchange resin (Dowex 50W × 2 (H⁺)), the column was washed with water, eluted with 200 ml of 1.5% ammonia water, small amount of antifoaming agent was added to the eluate, and the mixture was evaporated to dryness in vacuo to give 1.18 g of hygroscopic pale yellow powder. This was dissolved in 50 ml of methanol, the solution was stirred 2 hours at ambient temperature with activated charcoal, then the charcoal was removed, 2.00 g of p-toluenesulfonic acid was dissolved in the filtrate, methanol was evaporated in vacuo therefrom, and the residue was crystallized from isopropanol to give 1.40 g of colorless crystals, m.p. 167-169°C (decompn.). [α] 24 / D = +49.49° (C = 1.180, water). Elem Anal for C₂₀H₃₁NO₁₀·C₇H₈O₃S Calculated (%) C : 52.50 H : 6.36 N : 2.72 Found (%) C : 52.03 H : 6.49 N : 2.32 Example 9. 4-O-alpha-D-Glucopyranosyl-N-(beta-phenoxyethyl) moranoline To 50 ml of dimethylformamide were added 5 g of 4-O-alpha-D-glucopyranosylmoranoline and 6.4 g of anhydrous potassium carbonate. beta-Bromophenethol (7.7 g) was added thereto with stirring and the mixture was made to react at 110°C for 3 hours. The precipitate was removed by filtering the reaction solution. The filtrate was concentrated in vacuo, chloroform was added to the concentrate, the resulting precipitate was collected by filtration, dried with air, dissolved in water, and the solution was treated with a column of 100 ml of Dowex 50W × 2 (H⁺)). The column was well washed with water and eluted with 1N ammonia water. The solvent was evaporated in vacuo, the residue was dissolved in ethanol, the resulting very small amount of insoluble matter was removed by filtration, the filtrate was evaporated to remove ethanol in vacuo, and the residue was dried to give 4.3 g of the crystalline powder, m.p. 92-94°C,[α] 24 / D = +65.9° (c = 1%, water). Elem Anal for C₂₀H₃₁NO₁₀ Calculated (%) C : 53.93 H : 7.01 N : 3.14 Found (%) C : 53.43 H : 7.07 N : 3.05 Example 10. 4-O-alpha-D-Glucopyranosyl-N-(3-methyl-3-thienylallyl)moranoline Grignard reagent prepared from 13 g of vinyl bromide was made to react with 12.5 g of alpha-acetylthiophene to give 14.8 g of yellow oily carbinol. Tetrabromomethane (30 g) was added to it in 100 ml of acetonitrile and 25 g of triphenylphosphine was added little by little thereto with ice cooling and stirring and the mixture was stirred at 15-20°C for 2 hours. This was evaporated to dryness at not higher than 30°C in vacuo and the residue was extracted with ether. Ether was evaporated therefrom at not higher than 30°C and the residue was made to react at 50-60°C for 1 hour with 6 g of 4-O-alpha-D-glucopyranosylmoranoline and 12 g sodium bicarbonate in ethyleneglycol. Then the mixture was processed the same as in Example 9 to give 0.7 g of the product, m.p. 141-143°C. [α] 24 / D = b+30.8° (c = 1%, water). Example 11. 4-O-alpha-D-Glucopyranosyl-N-(2-oxobutyl)moranoline The same operation as in Example 9 was conducted using 1-bromo-2-butanone to give 2.1 g of the desired product, m.p. 101-105°C. [α] 24 / D = +73.3° (c = 1%, water). Example 12. 4-O-alpha-D-Glucopyranosyl-N-(4-carboxybenzyl)-moranoline p-toluenesulfonate . To 50 ml of dimethylforamide were added 4.5 g of 4-O-alpha-D-glucopyranosylmoranoline and 8.3 g of anhydrous potassium carbonate. To this was added 5 g of p-(bromomethyl)-benzoic acid with stirring and the mixture was made to react at 110°C for 5 hours. The reaction solution was filtered to remove the precipitate, the solvent was evaporated in vacuo from the filtrate, to the residue was added chloroform, the resulting insoluble matter was collected by decantation, dried in vacuo, then dissolved in water, the solution was passed through a column of 100 ml of Dowex 50W × 2 (H⁺) and the column was well washed with water and eluted with 1N ammonia water. The solvent was evaporated in vacuo, the residue was dissolved in small amount of water, and acetone was added to the solution. To this was added 3.0 g of p-toluenesulfonic acid monohydrate, the mixture was allowed to stand at 5°C, and the resulting precipitate was collected by filtration, washed with cold ethanol and dried to give 3.6 g of crystals. M.p. 251-253°C, [α] 24 / D +54.4° (c = 1%, water) Elem Anal for C₂₇H₃₇NO₁₄S Calculated (%) C : 54.09 H : 6.22 N : 2.34 Found (%) C : 53.59 H : 6.27 N : 2.24 Example 13. 4-O-alpha-D-Glucopyranosyl-N-allylmoranoline p-toluenesulfonate. A mixture of 2.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 4.24 g of anhydrous potassium carbonate, 10.0 g or allyl bromide and 20 ml of dimethylformamide was stirred at 60°C for 1 hour and heated with stirring at 90-100°C for 6 hours. After cooling, this was filtered to remove the insoluble matter and the filtrate was evaporated to dryness in vacuo. The residue was dissolved in 50 ml of water, the solution was passed through a column of 50 ml of Dowex 50W × 2 (H⁺), the column was washed with water, eluted with 30 ml of 1.4% ammonia water, small amount of antifoaming agent was added to the eluate, and the mixture was evaporated to dryness in vacuo to give 1.18 g of hygroscopic pale yellow powder. This was dissolved in 50 ml of methanol, the solution was stirred at ambient temperature for 2 hours with activated charcoal, then the charcoal was removed, 1.0 g of p-toluenesulfonic acid was dissolved in the filtrate, and methanol was evaporated from the solution to dryness in vacuo. The product was crystallized from isopropanol to give 0.74 g of colorless granules. M.p. 194-195°C. [α] 24 / D = +58.52° (c = 1.073, water). Elem Anal for C₁₅H₂₇NO₉·C₇H₈O₃S Calculated (%) C : 49.15 H : 6.56 N : 2.61 Found (%) C : 49.01 H : 6.47 N : 2.40 Example 14. 4-O-alpha-D-Glucopyranosyl-N-(4-phenoxybutyl)-moranoline. To 50 ml of dimethylformamide were added 5 g of 4-O-alpha-D-glucopyranosylmoranoline and 6.4 g of anhydrous potassium carbonate. To this was added 8.8 g of 4-phenoxybutyl bromide and the mixture was made to react at 110°C for 5 hours. The reaction solution was filtered to remove the precipitate and the solvent was evaporated in vacuo therefrom. To this was added chloroform, the resulting precipitate was collected by filtration dissolved in water, and the solution was partitioned with chloroform. The aqueous layer was evaporated to dryness in vacuo and ethanol was added to the residue. Small amount of insoluble matters was removed by filtration, then ethanol was evaporated therefrom, the residue was dissolved in water, and the solution was passed through a column of 100 ml of Dowex 50W × 2 (H⁺). The column was w washed with water, eluted with 1N ammonia water, the fractions were collected the solvent was evaporated in vacuo therefrom, and dried to give 5.5 g of crystalline powder, m.p. 85-87°C. [α] 24 / D = +60.1° (c = 1%, water). Elem Anal for C₂₂H₃₅NO₁₀ Calculated (%) C : 55.80 H : 7.45 N : 2.96 Found (%) C : 55.10 H : 7.40 N : 3.04 Example 15. 4-O-alpha-D-Glucopyranosyl-N-(beta-phenylthioethyl)moranoline. The same operation as in Example 14 was conducted using 2-phenylthioethyl bromide to give 3.3 g of desired product, m.p. 96-98°C. [α] 24 / D = +70.1° (c = 1%, water). Elem Anal for C₂₀H₃₁NO₉S Calculated (%) C : 52.05 H : 6.77 N : 3.04 Found (%) C : 51.56 H : 6.99 N : 3.21 Example 16. 4-O-alpha-D-Glucopyranosyl-N-[beta-( 4-ethoxycarbonylphenoxy)ethyl]moranoline. The same operation as in Example 14 was conducted using beta-(4-ethoxycarbonylphenoxy)ethyl bromide to give 3.8 g of the desired product, m.p. 123-125°C. [α] 24 / D = +60.1° (C = 1%, water). Elem Anal for C₂₃H₃₅NO₁₂ Calculated (%) C : 53.38 H : 6.82 N : 2.71 Found (%) C : 53.01 H : 6.91 N : 2.84 Example 17. 4-O-alpha-D-Glucopyranosyl-N-nonylmoranoline hydrate. A mixture of 1.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 2.00 g of anhydrous potassium carbonate, 2.00 g of 1-bromononane, and 15 ml of dimethyl sulfoxide was stirred at ambient temperature for 1 hour and heated with stirring at 100-110°C for 3 hours. After the reaction, the mixture was filtered to remove insoluble matters, the filtrate was evaporated in vacuo to remove dimethyl sulfoxide, the residue was washed twice with 10 ml of ether each, and the substance insoluble in ether was dissolved in 20 ml of water. This solution was passed through a column of 30 ml of Dowex 50W × 2 (H⁺), the column was washed with water, eluted with 200 ml of 1.4% ammonia water, to the eluate was added small amount of antifoaming agent, and the mixture was evaporated in vacuo to dryness to give 0.30 g of colorless powder. Purification was conducted by a high performance liquid chromatography (Nucleosil 5 NH₂; column size: 10 × 105 mm; acetonitrile-water = 7:3; 1.0 ml/min, RI detector) to give 0.10 g of the product. M.p. 112-113°C. [α] 24 / D = +58.64° (c = 0.665, water.). Elem Anal for C₂₁H₄₁NO₉·H₂O Calculated (%) C : 53.72 H : 9.23 N : 2.98 Found (%) C : 54.07 H : 9.16 N : 3.01 Example 18. 4-O-alpha-D-Glucopyranosyl-N-(4-methoxycarbonylbutyl)-moranoline p-toluenesulfonate. To 50 ml of dimethylformamide were added 5 g of 4-O-alpha-D-glucopyranosylmoranoline and 6.4 g of anhydrous potassium carbonate. To this was added 7.5 g of methyl 5-bromovalerate and the mixture was made to react at 110°C for 3 hours. The reaction solution was filtered to remove the precipitate and the solvent was evaporated in vacuo therefrom. To the residue was added chloroform, the mixture was decantated to remove chloroform-soluble matters, the precipitate thus obtained was dried in vacuo, dissolved in water, and the solution was passed through a column of 100 ml of Dowex 50W × 2 (H⁺). The column was well washed with water, eluted with 1N ammonia water, the fractions were collected, the solvent was evaporated therfrom in vacuo, and the residue was dried. To this was added 100 ml of ethanol, then small amount of methanol was further added, and to the resulting solution was added 3.8 g of p-toluenesulfonic acid (monohydrate). The mixture was concentrated, filtered to collect the crystals, and the crystals were washed with ethanol and dried to give 5.9 g of crystalline powder, m.p. 114-116°C. [α] 24 / D = +45.3° (c = 1%, water). Elem Anal for C₂₅H₄₁NO₁₄S Calculated (%) C : 49.09 H : 6.76 N : 2.29 Found (%) C : 48.39 H : 7.04 N : 2.05 Example 19. 4-O-alpha-D-Glucopyranosyl-N-phenethylmoranoline p-toluenesulfonate. A mixture of 2.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 3.39 g of anhydrous potassium carbonate, 5.69 g of phenethyl bromide, and 20 ml of dimethylformamide was stirred at 60°C for 1 hour and then heated with stirring at 100-110°C for 6 hours. The reaction solution was filtered when it was still hot, the insoluble matter was washed with small amount of dimethylformamide, the washing was combined with the filtrate, and dimethylformamide was evaporated in vacuo therefrom. The residue was washed twice with 20 ml of ether each. The ether-insoluble matters were dissolved in water, the solution was passed through a column of 50 ml of Dowex 50W × 2 (H⁺), the column was washed with water, and eluted with 300 ml of 1.4% ammonia water. Small amount of antifoaming agent was added to the eluate and the mixture was evaporaed to dryness in vacuo to give 0.8 g of pale yellow powder. This was dissolved in 20 ml of methanol, the solution was stirred at ambient temperature for 2 hours with activated charcoal, the charcoal was removed by filtration, 0.80 g of p-toluenesulfonic acid was dissolved in the filtrate, methanol was evaporated in vacuo therefrom, and the residue was dried. This was recrystallized from isopropanol twice to give 0.42 g of colorless crystals. M.p. 129-130°C. [α] 24 / D = +50.75° (c = 0.930, water) Elem Anal for C₂₀H₃₁NO₉·C₇H₈O₃S·H₂O Calculated (%) C : 52.33 H : 6.67 N : 2.26 Found (%) C : 52.33 H : 6.87 N : 2.11 Example 20. 4-O-alpha-D-Glucopyranosyl-N-cinnamylmoranoline p-toluenesulfonate. To 50 ml of dimethylformamide were added 5 g of 4-O-alpha-D-glucopyranosylmoranoline and 6.4 g of anhydrous potassium carbonate. To this was added 7.6g of cinnamyl bromide and the mixture was made to react at ambient temperature for 1 hour. The reaction solution was filtered to remove the precipitate and the solvent was removed from the filtrate in vacuo. Water was added to the residue, the mixture was well stirred, and partitioned by addition of chloroform thereto. The aqueous layer was passed through a column of 100 ml of Dowex 50W × 2 (H⁺) The column was well washed with water and eluted with 1N ammonia water. The solvent was evaporated from the eluate. The residue was dissolved in methanol and, after addition of 2.5 g of p-toluenesulfonic acid thereto, the mixture was concentrated until crystals separated out. The resulting crystals were collected by filtration, washed with ethanol, and dried to give 2.0 g of crystalline powder, m.p. 212-214°C. [α] 24 / D = +35.2° (c = 1%, water). Elem Anal for C₂₈H₃₉NO₁₂S Calculated (%) C : 54.80 H : 6.41 N : 2.28 Fopund (%) C : 54.64 H : 6.51 N : 2.09 Example 21. 4-O-alpha-D-Glucopyranosyl-N-[p-(3-hydroxypropenyl)-cinnamyl]moranoline hydrochloride. The same operation as in Example 20 was conducted using p-(3-hydroxypropenyl)-cinnamyl bromide to give 0.5 g of the desired product, m.p. 220-225°C. [α] 24 / D = +26.1° (c = 1%, water). Elem Anal for C₂₄H₃₅NO₁₀·HCl Calculated (%) C : 53.98 H : 6.80 N : 2.62 Found (%) C : 53.41 H : 7.11 N : 2.89 Example 22. 4-O-alpha-D-Glucopyranosyl-N-(2-hydroxy-3-phenoxypropyl)moranoline p-toluenesulfonate hydrate. A mixture of 2.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 5.54 g of glycidyl phenyl ether and 30 ml of dimethylformamide was heated with stirring at 100-110°C for 7.5 hours. Dimethylformamide was evaporated therefrom in vacuo. The residue was washed twice with 10 ml of ether each. The ether-insoluble matters were dissolved in 30 ml of water, the solution was passed through a column o f 30 ml of Dowex 50W × 2 (H⁺), the column was washed with water until the washing became neutral, and eluted with 200 ml of 1.4% ammonia water. Small amount of antifoaming agent was added to the eluate and the mixture was concentrated to dryness in vacuo to give 0.5 g of residue. This was dissolved in 20 ml of methanol, 0.5 g of p-toluenesulfonic acid was dissolved therein, methanol was evaporated in vacuo therefrom, and the residue was dried, washed with ether, and crystallized from isopropanol to give 0.3 g of colorless cubes, m.p. 104°C. [α] 24 / D = +49.61° (c = 1.032, water). Elem Anal for C₂₁H₃₃NO₁₁·C₇H₈O₃S·H₂O Calculated (%) C : 50.52 H : 6.51 N : 2.10 Found (%) C : 50.58 H : 6.46 N : 1.96 Example 23. 4-O-alpha-D-Glucopyranosyl-N-(beta-ethoxy)ethylmoranoline p-toluenesulfonate. Ten grams of hepta-O-benzyl derivative of 4-O-alpha-D-glucopyranosyl-N (beta-hydroxy)ethylmoranoline was made to react with 20 ml of thionyl chloride at 80°C for 3 hours, the mixture was evaporated to dryness in vacuo, the residue was added to 200 ml of ethanol in which 2 g of sodium was dissolved, and the mixture was made to react at 50°C for 5 hours. Ethanol was removed therefrom, the residue was dissolved in benzene, and washed with water. The resulting reaction product was purified with a column of silica gel using chloroform-ethyl acetate (5:1) as a developer. The resulting product (9 g) was dissolved in ethanol and subjected to catalytic hydrogenation using palladium as a catalyst. The catalyst was filtered off, the filtrate was evaporated, the residue was dissolved in water, and the solution was passed through a column of 100 ml of Dowex 50W × 2 (H⁺). The column was well washed with water and eluted with 1N ammonia water. The eluate was evaporated in vacuo the residue was dissolved in ethanol, 2.5 g of p-toluenesulfonic acid (monohydrate) was added, and the mixture was concentrated until crystals separated out. The resulting crystals were collected by filtration, washed with ethanol, and dried to give 2.3 g of crystalline powder, m.p. 117-119°C. [α] 24 / D = +85.6° (c = 1%, water). Example 24. 4-O-alpha-D-glucopyranosyl-N-(beta-dimethylaminoethyl)moranoline p-toluenesulfonate. Ten grams of hepta-O-benzyl derivative of 4-O-alpha-D-glucopyranosyl-N-(beta-hydroxyethyl)moranoline was made into a chloro compound by the same way as in Example 23, then made to react with diethylamine in ether, and the mixture was evaporated to dryness followed by the same treatment as in Example 23 to give 1.8 g of desired product. M.p. 161-163°C. [α] 24 / D = +80.2° (c = 1%, water). Example 25. 4-O-alpha-D-Glucopyranosyl-N-(p-methylbenzyl)-moranoline p-toluenesulfonate. A mixture of 2.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 4.24 g of anhydrous potassium carbonate, 3.61 g of p-methylbenzyl bromide and 20 ml of dimethylformamide was stirred at 60°C for 1 hour and heated at 100-110°C with stirring. After cooling, the mixture was filtered to remove insoluble matters, and the filtrate was evaporated to dryness in vacuo. The residue was washed twice with each 10 ml ether, the ether-insoluble matters were dissolved in 50 ml of water, the solution was passed through a column of 50 ml of Dowex 50W × 2 (H⁺), the column was washed with water, and eluted with 300 ml of 1.4% ammonia water. Small amount of antifoaming agent was added to the eluate and the mixture was evaporated to dryness in vacuo to give 1.18 g of hygroscopic pale yellow powder. This was dissolved in 50 ml of methanol, the solution was stirred with activated charcaol at ambient temperature for 2 hours, the charcoal was removed, 2.00 g of p-toluenesulfonic acid was dissolved in the solution, methanol was evaporated therefrom in vacuo, and the residue was dried followed by crystallizing from isopropanol to give 1.46 g of colorless crystals. M.p. 158-160°C. [α] 24 / D = +49.11° (c = 1.124, water). Elem Anal for C₂₀H₃₁NO₉·C₇H₈O₃S Calculated (%) C : 53.90 H : 6.53 N : 2.33 Found (%) C : 53.88 H : 6.31 N : 2.09 Example 26. 4-O-alpha-D-Glucopyranosyl-N-pentadecylmoranoline p-toluenesulfonate. A mixture of 2.00 g of 4-O-alpha-D-glucopyranosylmoranoline, 3.40 g of anhydrous potassium carbonate, 3.3 g of 1-bromopentadecane and 20 ml of dimethylformamide was stirred at 60-70°C for 1 hour and heated with stirring at 100-110°C for 3 hours. The mixture was filtered to remove the insoluble matters and the filtrate was evaporated to dryness in vacuo. The residue was washed twice with each 10 ml of ether. To the ether-insoluble matter was added 30 ml of water, the mixture was warmed to make it dissolved, and allowed to cool. Gel-like substances separated out therefrom were collected by filtration, dissolved in 30 ml of methanol, activated charcoal was added thereto, the mixture was stirred 2 hours at ambient temperature, the charcoal was removed, 0.80 g of p-toluenesulfonic acid was added to the solution, and the mixture was evaporated to dryness in vacuo. The residue was crystallized from isopropanol to give 0.40 g of desired product, m.p. 173-175°C. [α] 24 / D = +43.19° (c = 1.102, methanol). Elem Anal for C₂₇H₅₃NO₉·C₇H₈O₃S Calculated (%) C : 57.69 H : 8.68 N : 1.98 Found (%) C : 57.22 H : 8.74 N : 1.94

Claims: Glucosylmoranoline derivatives represented by the following general formula (I) wherein B, A and R have the following meanings : B : Chain or cyclic C₁₋₁₅ alkylene, C₂₋₁₅ alkenylene or C₂₋₁₅ alkynylene, unsubstituted or substituted with at least one substituent selected from halogen, hydroxyl, mercapto, amino, aromatic hydrocarbon residue or heterocyclic residue; A : O, S, NH, NR, C=O or a combination of two or more of them or a direct combination of B with R; and R : A group selected from the following (1) to (3) : (1) Chain or cyclic alkyl, alkenyl or alkynyl, unsubstituted or substituted with at least one substituent selected from halogen, hydroxyl, mercapto, amino, aromatic hydrocarbon residue or heterocyclic residue; (2) phenyl or naphthyl unsubstituted or substituted with at least one substituent selected from chain or cyclic alkyl, alkenyl or alkynyl, halogen, hydroxyl, mercapto, amino, carboxyl, alkoxycarbonyl, aromatic hydrocarbon residue or heterocyclic residue; (3) heterocyclic radical selected from pyridinyl, morpholinyl, piperidinyl and benzimidazolyl, unsubstituted or substituted with at least one substitutent selected from chain or cyclic alkyl, alkenyl or alkynyl, halogen, hydroxyl, mercapto, amino, carboxyl, alkoxycarbonyl, aromatic hydrocarbon residue or heterocyclic residue, except the case where B-A-R is any of the following (1) to (3) : (1) hydrogen; (2) C₁-C₃ alkyl; and (3) chain or cyclic hydrocarbon having one or more hydroxyl groups. Glucosylmoranoline derivative selected from 4-0-alpha-D-Glucopyranosyl-N-(p-methoxybenzyl) moranoline and 4-0-alpha-D-Glucopyranosyl-N-(3-methyl-3-thienyl-(2)-allyl) moranoline.

Inventors: EZURE, YOHJI, FUJITA, YUKIO, SUGIYAMA, MAKOTO, YOSHIKUNI, YOSHIAKI
Applicants: NIPPON SHINYAKU COMPANY, LIMITED
Application year: 1987
Main classification: C07H17
IPC codes: A61K31, A61P3, C07H17